Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690701 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 4 study of Chronic Plaque Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
- 12
- Study locations
NCT02690701: Completed Phase 4 study of Chronic Plaque Psoriasis, sponsored by Novartis Pharmaceuticals.
NCT02690701 is a Phase 4 study of Chronic Plaque Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 91 participants, below the 1,117-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690701, a Phase 4 study of Chronic Plaque Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
Primary Outcome
Change from baseline in the target to background ratio from the whole aorta. Effect of secukinumab 300 mg subcutaneous (sc) compared to placebo on aortic vascular inflammation with respect to the change from baseline in the target (arterial vascular uptake) to background (venous blood pool) ratio from the aorta. The primary analysis time point was at Week 12. Increased aortic vascular inflammation as measured by (18F) fluorodeoxyglucose positron emission tomography with computer assisted tomog
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- DRUG Secukinumab 300 mg
Study Locations (12)
California
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Santa Ana
New York
- Novartis Investigative Site - Buffalo
- Novartis Investigative Site - New York
Oregon
- Novartis Investigative Site - Portland
- Novartis Investigative Site - Portland
Texas
- Novartis Investigative Site - Dallas
- Novartis Investigative Site - Houston
Maryland
- Novartis Investigative Site - Rockville
Missouri
- Novartis Investigative Site - St Louis
Pennsylvania
- Novartis Investigative Site - Exton
Utah
- Novartis Investigative Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2018-02-19 |
| Phase | Phase 4 |
What the finished NCT02690701 record still lists
NCT02690701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,117-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02690701 lists 12 locations in 8 states (California, New York, Oregon).
Frequently Asked Questions
What is clinical trial NCT02690701 about?
NCT02690701 is a clinical study titled "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis". This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
What is the current status of trial NCT02690701?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2016-02-10. Estimated completion is 2018-02-19.
What conditions does trial NCT02690701 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT02690701?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab 300 mg (DRUG).
Who is sponsoring clinical trial NCT02690701?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690701 being conducted?
This trial has 12 study locations across California, Maryland, Missouri, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
COMPLETED · Phase 4
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Chronic Plaque Psoriasis (Ps) Registry
COMPLETED
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI